Size | Price | Stock | Qty |
---|---|---|---|
1mg |
|
||
5mg |
|
||
Other Sizes |
|
ln Vitro |
The invasion ability of A549 cells was greatly reduced by HET0016 or WIT 002, both of which were applied in the experiment due to the cells' strong ω-hydroxylation activity of arachidonic acid [2]. RPTC normal renal epithelial cells are not susceptible to WIT 002 or HET0016-induced inhibition of proliferation, however 786-O and 769-P renal cancer cell proliferation can be inhibited [2][3].
|
---|---|
ln Vivo |
The effect of the 20-HETE antagonist WIT 002 on the growth of 786-O clear cell renal carcinoma was studied in an ectopic mice model of renal malignancies. Daily treatment of WIT 002 to athymic nude mice subcutaneously implanted with 786-O cells effectively reduced tumor growth. Tumor development was suppressed by 84%±128%. Of note, in these tests, WIT 002 treatment was began just 7-14 days after tumor inoculation and was rather large by 0.1 cm. Therefore, WIT 002 can successfully block the formation of rather advanced cancers [3].
|
References |
[1]. Ming Yua . et al. Effects of a 20-HETE antagonist and agonists on cerebral vascular tone. Eur J Pharmacol. 2004 Feb 23;486(3):297-306.
[2]. Wei Yu, et al. Cytochrome P450 ω-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer. Cancer Chemother Pharmacol. 2011 Sep; 68(3): 619-29. [3]. Anna Alexanian, et al. Down-regulation of 20-HETE Synthesis and Signaling Inhibits Renal Adenocarcinoma Cell Proliferation and Tumor Growth. Anticancer Res. 2009 October ; 29(10): 3819-3824 |
Additional Infomation |
20-HeDE is a HEDE.
|
Molecular Formula |
C20H36O3
|
---|---|
Molecular Weight |
324.4980
|
Exact Mass |
324.266
|
CAS # |
240427-90-1
|
PubChem CID |
10426436
|
Appearance |
Typically exists as solid at room temperature
|
LogP |
5.8
|
Hydrogen Bond Donor Count |
2
|
Hydrogen Bond Acceptor Count |
3
|
Rotatable Bond Count |
17
|
Heavy Atom Count |
23
|
Complexity |
308
|
Defined Atom Stereocenter Count |
0
|
SMILES |
C(CCC/C=C\CCCCC(=O)O)CCC/C=C\CCCCO
|
InChi Key |
RYHYNNWEPYGEEH-WGEIWTTOSA-N
|
InChi Code |
InChI=1S/C20H36O3/c21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20(22)23/h8-11,21H,1-7,12-19H2,(H,22,23)/b10-8-,11-9-
|
Chemical Name |
(6Z,15Z)-20-hydroxyicosa-6,15-dienoic acid
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
---|---|
Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.0817 mL | 15.4083 mL | 30.8166 mL | |
5 mM | 0.6163 mL | 3.0817 mL | 6.1633 mL | |
10 mM | 0.3082 mL | 1.5408 mL | 3.0817 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.